|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
KR20140051357A
(ko)
*
|
2011-08-26 |
2014-04-30 |
애로우헤드 리서치 코오포레이션 |
Ｉｎ Ｖｉｖｏ 핵산 전달용 폴리(비닐 에스테르) 고분자
|
|
EP3640332A1
(en)
|
2011-08-29 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(en)
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
JP2015501844A
(ja)
|
2011-12-16 |
2015-01-19 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
|
|
US8796405B2
(en)
|
2012-01-18 |
2014-08-05 |
Wisconsin Alumni Research Foundation |
Degradable polycations derived from amino acid vinyl esters
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
AU2012377385A1
(en)
*
|
2012-04-18 |
2014-01-23 |
Arrowhead Research Corporation |
Poly(acrylate) polymers for in vivo nucleic acid delivery
|
|
ES2921623T3
(es)
|
2012-11-26 |
2022-08-30 |
Modernatx Inc |
ARN modificado terminalmente
|
|
SG10201706960TA
(en)
|
2013-02-28 |
2017-10-30 |
Arrowhead Res Corp |
Organic compositions to treat epas1-related diseases
|
|
HK1220368A1
(zh)
|
2013-03-13 |
2017-05-05 |
Cour Pharmaceuticals Development Company |
用於治疗炎症的免疫修饰性颗粒
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
CA2921162A1
(en)
|
2013-05-01 |
2014-11-06 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
WO2015021092A1
(en)
|
2013-08-07 |
2015-02-12 |
Arrowhead Research Corporation |
Polyconjugates for delivery of rnai triggers to tumor cells in vivo
|
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
WO2015168172A1
(en)
|
2014-04-28 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
US10280423B2
(en)
|
2014-05-01 |
2019-05-07 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating complement factor B expression
|
|
AU2015252841B2
(en)
|
2014-05-01 |
2020-03-19 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating growth hormone receptor expression
|
|
MX382230B
(es)
|
2014-05-01 |
2025-03-13 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
|
|
JP6665111B2
(ja)
|
2014-05-01 |
2020-03-13 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
Ｐｋｋ発現を調節するための組成物及び方法
|
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
WO2016014846A1
(en)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
WO2016040748A1
(en)
|
2014-09-12 |
2016-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for detection of smn protein in a subject and treatment of a subject
|
|
SG10202105989WA
(en)
|
2015-05-29 |
2021-07-29 |
Arrowhead Pharmaceuticals Inc |
Compositions and methods for inhibiting gene expression of hif2alpha
|
|
PE20180800A1
(es)
|
2015-07-10 |
2018-05-09 |
Ionis Pharmaceuticals Inc |
Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
|
|
KR20180038465A
(ko)
|
2015-08-07 |
2018-04-16 |
애로우헤드 파마슈티컬스 인코포레이티드 |
Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
|
|
HK1255699A1
(zh)
|
2015-09-24 |
2019-08-23 |
Ionis Pharmaceuticals, Inc. |
Kras表达的调节剂
|
|
JOP20160211B1
(ar)
|
2015-10-01 |
2021-08-17 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
|
EP3365009A4
(en)
|
2015-10-22 |
2019-07-03 |
ModernaTX, Inc. |
VACCINES AGAINST HERPES SIMPLEX VIRUS
|
|
MD3718565T2
(ro)
|
2015-10-22 |
2022-09-30 |
Modernatx Inc |
Vaccinuri împotriva virusului respirator
|
|
TN2018000154A1
(en)
|
2015-10-22 |
2019-10-04 |
Modernatx Inc |
Respiratory syncytial virus vaccine
|
|
WO2017070601A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
AU2016342048B2
(en)
|
2015-10-22 |
2022-09-08 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
SI4119569T1
(sl)
|
2015-11-06 |
2024-10-30 |
Ionis Pharmaceuticals, Inc. |
Konjugirane protismiselne spojine za uporabo v terapiji
|
|
EP3370708A4
(en)
|
2015-11-06 |
2019-06-26 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF APOLIPOPROTEIN (A) EXPRESSION
|
|
WO2017112943A1
(en)
|
2015-12-23 |
2017-06-29 |
Modernatx, Inc. |
Methods of using ox40 ligand encoding polynucleotides
|
|
WO2017120612A1
(en)
|
2016-01-10 |
2017-07-13 |
Modernatx, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
|
US10246709B2
(en)
|
2016-03-07 |
2019-04-02 |
Arrowhead Pharmaceuticals, Inc. |
Targeting ligands for therapeutic compounds
|
|
CA3023764A1
(en)
|
2016-06-06 |
2017-12-14 |
Arrowhead Pharmaceuticals, Inc. |
5'-cyclo-phosphonate modified nucleotides
|
|
ES2935658T3
(es)
|
2016-07-15 |
2023-03-09 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para la modulación de SMN2
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
JP6989521B2
(ja)
|
2016-09-02 |
2022-01-05 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
標的化リガンド
|
|
KR20190065341A
(ko)
|
2016-10-06 |
2019-06-11 |
아이오니스 파마수티컬즈, 인코포레이티드 |
올리고머 화합물들의 접합 방법
|
|
UY37565A
(es)
|
2017-01-10 |
2018-07-31 |
Arrowhead Pharmaceuticals Inc |
Agentes de iarn alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y métodos de uso
|
|
EP3573623B1
(en)
|
2017-01-30 |
2026-03-04 |
Arrowhead Pharmaceuticals, Inc. |
Compositions and methods for inhibition of factor xii gene expression
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
WO2018232357A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna formulations
|
|
KR20200024793A
(ko)
|
2017-07-06 |
2020-03-09 |
애로우헤드 파마슈티컬스 인코포레이티드 |
알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
TN2020000039A1
(en)
|
2017-09-11 |
2021-10-04 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
|
|
PE20201287A1
(es)
|
2017-09-14 |
2020-11-24 |
Arrowhead Pharmaceuticals Inc |
Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso
|
|
JP7473472B2
(ja)
|
2017-10-17 |
2024-04-23 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物
|
|
US20200392510A1
(en)
|
2018-01-15 |
2020-12-17 |
Ionis Pharmaceuticals, Inc. |
Modulators of dnm2 expression
|
|
CA3090901A1
(en)
|
2018-02-12 |
2019-08-15 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
JP7438135B2
(ja)
|
2018-05-09 |
2024-02-26 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｆｘｉの発現を低下させるための化合物及び方法
|
|
EP3823725A4
(en)
|
2018-07-17 |
2023-05-10 |
Aronora, Inc. |
METHODS FOR SAFELY REDUCING THROMBOPOIETIN
|
|
EP3833397A4
(en)
|
2018-08-08 |
2023-06-14 |
Arcturus Therapeutics, Inc. |
COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS
|
|
IL281597B1
(en)
|
2018-09-19 |
2026-05-01 |
Arrowhead Pharmaceuticals Inc |
RNAI agents for suppressing 17 beta-HSD type 13 expression, (HASD17B13), their compositions and uses
|
|
TWI869213B
(zh)
|
2018-09-19 |
2025-01-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
US20220273691A1
(en)
|
2018-12-21 |
2022-09-01 |
Ionis Pharmaceuticals, Inc. |
Modulators of hsd17b13 expression
|
|
EP3908288A4
(en)
|
2019-01-09 |
2023-12-20 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
|
|
EP4707394A3
(en)
|
2019-02-07 |
2026-04-29 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for hepatitis b virus infection
|
|
EP3980540A4
(en)
|
2019-06-06 |
2023-11-01 |
Arrowhead Pharmaceuticals, Inc. |
METHOD FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
|
|
WO2020255008A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
|
|
US20220305117A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
|
JP7757277B2
(ja)
|
2019-10-14 |
2025-10-21 |
アストラゼネカ・アクチエボラーグ |
Ｐｎｐｌａ３発現のモジュレーター
|
|
PH12022552258A1
(en)
|
2020-02-28 |
2023-11-20 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating smn2
|
|
BR112022019241A2
(pt)
|
2020-03-26 |
2022-11-16 |
Arrowhead Pharmaceuticals Inc |
Agentes de rnai para inibição da expressão de pnpla3, composições farmacêuticas dos mesmos e métodos de uso
|
|
CA3176196A1
(en)
|
2020-04-21 |
2021-10-28 |
Flagship Pioneering, Inc. |
Bifunctional molecules and methods of using thereof
|
|
TW202218687A
(zh)
|
2020-09-11 |
2022-05-16 |
美商愛羅海德製藥公司 |
骨骼肌遞送載體及其使用方法
|
|
IL301185A
(en)
|
2020-09-11 |
2023-05-01 |
Arrowhead Pharmaceuticals Inc |
Lipid conjugates for the delivery of therapeutic agents
|
|
AU2021342155A1
(en)
|
2020-09-11 |
2023-04-13 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
|
|
JP7820374B2
(ja)
|
2020-11-18 |
2026-02-25 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
アンジオテンシノーゲン発現を調節するための化合物及び方法
|
|
BR112023020626A2
(pt)
|
2021-04-08 |
2023-12-19 |
Arrowhead Pharmaceuticals Inc |
Agentes de rnai para inibir a expressão do receptor para produtos finais de glicação avançada, composições dos mesmos e métodos de uso
|
|
EP4326334A1
(en)
|
2021-04-23 |
2024-02-28 |
GanNA Bio, Inc. |
Glycan modified nucleic acids, methods of preparation, and therapeutic uses
|
|
KR20240014067A
(ko)
|
2021-05-28 |
2024-01-31 |
애로우헤드 파마슈티컬스 인코포레이티드 |
뮤신 5AC (MUC5AC)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
|
|
US11549112B1
(en)
|
2021-06-21 |
2023-01-10 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
|
|
CA3233755A1
(en)
|
2021-10-01 |
2023-04-06 |
Adarx Pharmaceuticals, Inc. |
Prekallikrein-modulating compositions and methods of use thereof
|
|
WO2023161350A1
(en)
|
2022-02-24 |
2023-08-31 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
WO2023245060A2
(en)
|
2022-06-15 |
2023-12-21 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and methods of use
|
|
JP2026511018A
(ja)
|
2023-03-21 |
2026-04-10 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
補体因子Ｂ（ＣＦＢ）の発現を阻害するためのＲＮＡｉ剤、その医薬組成物、及び使用方法
|
|
CN121285630A
(zh)
|
2023-04-20 |
2026-01-06 |
阿达尔克斯制药有限公司 |
Mapt调节组合物及其使用方法
|
|
KR20260021635A
(ko)
|
2023-05-12 |
2026-02-13 |
아다르엑스 파마슈티컬스, 인크. |
Nmda 리간드 접합 화합물 및 이의 용도
|
|
IL324720A
(en)
|
2023-05-26 |
2026-01-01 |
Adarx Pharmaceuticals Inc |
SOD1 modulators and methods of using them
|
|
CN121712891A
(zh)
|
2023-06-20 |
2026-03-20 |
阿达尔克斯制药有限公司 |
Lrrk2调节组合物及其使用方法
|
|
WO2025049773A1
(en)
|
2023-08-30 |
2025-03-06 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of inhibin subunit beta e (inhbe), pharmaceutical compositions thereof, and methods of use
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
TW202530408A
(zh)
|
2023-09-29 |
2025-08-01 |
美商英西特羅公司 |
用於治療非酒精性脂肪肝病的組合物與方法
|
|
WO2025137390A1
(en)
|
2023-12-20 |
2025-06-26 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of activin receptor-like kinase 7 (alk7), compositions thereof, and methods of use
|
|
US12553050B2
(en)
|
2024-03-22 |
2026-02-17 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression
|
|
WO2025212467A1
(en)
|
2024-03-31 |
2025-10-09 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use
|
|
US20250333742A1
(en)
|
2024-04-25 |
2025-10-30 |
Insitro, Inc. |
Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease
|
|
WO2025265013A2
(en)
|
2024-06-20 |
2025-12-26 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of use
|
|
WO2026044017A2
(en)
|
2024-08-21 |
2026-02-26 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|